Beta Bionics Q2 Sales Surge 38% to $32M, Gross Margin Hits 59%, Cash Runway Extended to 2028
BBNX sits 77% above its 52-week low of $8.8.
Summary
Beta Bionics reported Q2 2026 revenue of $32.0 million, a 38% increase, with gross margin improving to 59%. Cash runway now extends to 2028, but operating losses widened on higher commercial investment. The Mint patch pump and T2D expansion remain on track.
Key Events · Earnings and Guidance · BBNX
-
Q2 Revenue Jumps 38% to $32M
Net sales reached $32.0 million, up from $23.2 million in Q2 2025, driven by a 153% increase in new patient starts and higher single-use product sales from the growing installed base.
-
Gross Margin Expands to 59%
Gross margin improved to 59% from 54% a year ago, reflecting production scale benefits, lower warranty expense, and better cost absorption.
-
Cash Runway Extended to H1 2028
With $225.2 million in cash, equivalents, and investments, management now expects sufficient liquidity to fund operations through the first half of 2028, reducing near-term capital needs.
-
Operating Loss Widens on Commercial Push
Operating loss grew to $25.6 million from $19.9 million, as sales and marketing expenses nearly doubled to $24.6 million to support territory expansion and customer care.
Analysis · BBNX · Industrial Applications And Services
A standout quarter for Beta Bionics saw revenue climb 38% year-over-year to $32 million, fueled by a 153% surge in new patient starts. Gross margin expanded to 59%, reflecting improved manufacturing scale and lower warranty costs. The company extended its cash runway through the first half of 2028, reducing near-term dilution risk. However, operating losses widened as sales and marketing spend nearly doubled to support commercial expansion. The filing also confirms the Mint patch pump remains on track for a late-2027 launch and that a pivotal T2D trial began enrolling in July. Against this backdrop, the company continues to remediate a January 2026 FDA Warning Letter, which does not restrict current operations but adds regulatory overhang.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BBNX was trading at $15.61 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $676M. The 52-week trading range was $8.80 to $32.71. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.